[Ip-health] New study on 2 Hepatitis C medicines' impact on health spending
bagozzid at who.int
Wed Jun 1 00:57:17 PDT 2016
New study published yesterday in PLOS Medicine, by Suzanne Hill (WHO) et al, shows that the prices of sofosbuvir and ledipasvir/sofosbuvir vary greatly between countries worldwide, raising serious concerns about the viability of reducing the global hepatitis C burden. For example, after adjusting for average 2015 exchange rates and purchasing power, the study reveals that the cost of treating the entire hepatitis C infected population in each of the 30 countries examined would range from 10.5% of total pharmaceutical expenditure in the Netherlands to 190.5% in Poland.
See study here: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002032
More information about the Ip-health